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Abstract
Antibiotic-resistant bacterial pathogens threaten public health. Because many anti-biotics target 
specific bacterial enzymes or reactions, corresponding genes may mutate under selection and lead 
to antibiotic resistance. Accordingly, antimicrobials that selectively target overall microbial cell 
integrity may offer alternative approaches to therapeutic design. Naturally occurring mammalian 
α- and θ-defensins are potent, non-toxic microbicides that may be useful for treating infections by 
antibiotic-resistant pathogens, because certain defensin peptides disrupt bacterial but not 
mammalian cell membranes. To test this concept, clinical isolates of methicillin-resistant 
Staphylococcus aureus (MRSA), including vancomycin heteroresistant strains, and ciprofloxacin-
resistant Pseudomonas aeruginosa (CipR-PA) were tested for sensitivity to α-defensins Crp-4, 
RMAD-4, and HNPs 1–3, and to RTD-1, a macaque θ-defensin-1. In vitro, 3 µM Crp-4, RMAD-4, 
and RTD-1 reduced MRSA cell survival by 99%, regardless of vancomycin susceptibility. For PA 
clinical isolates that differ in fluoroquinolone resistance and virulence phenotype, peptide efficacy 
was independent of strain ciprofloxacin resistance, site of isolation, or virulence factor expression. 
Thus, Crp-4, RMAD-4, and RTD-1 are effective in vitro antimicrobials against clinical isolates of 
MRSA and CipR-PA, perhaps providing templates for development of α- and θ-defensin-based 
microbicides against antibiotic resistant or virulent infectious agents.
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INTRODUCTION
The economic costs of antimicrobial resistant infections has reached nearly $30 billion 
dollars per year in the US1. In 2002, of health care–associated infections that resulted in 
99,000 deaths, approximately 16% were reported to the CDC as resistant to antibiotics2–5. 
The increase in antibiotic resistance narrows the options for the treatment of infections 
caused by multidrug-resistant bacteria5, 6.
The Gram-negative bacterium Pseudomonas aeruginosa (PA) is a leading cause of 
nosocomial infections for which the fluoroquinolone antibiotics, e.g. ciprofloxacin, are 
commonly prescribed. Over the past decade, the prevalence of ciprofloxacin-resistant (CipR) 
PA strains has increased 3-fold in parallel to the trend of prescribing this antibiotic class7. 
Upwards of 30% of clinical PA strains are multidrug-resistant, and some are resistant to all 
available antibiotics5, 8–10. In addition, PA strains have an arsenal of virulence factors, 
including a type III secretion system (TTSS) that induces cytotoxicity and expression of 
ExoU or ExoS effector proteins which are virulence factors that influence disease severity 
by phagocyte evasion during acute infections11.
Methicillin-resistant Staphylococcus aureus (MRSA) are Gram-positive bacteria with 
resistance to all β-lactam compounds except one, accounting for nearly 60% of all clinical 
isolates from ICU patients12. Limited to the healthcare setting in the past, new, more 
virulent MRSA strains have emerged in the community, and they are now responsible for 
infections across both the community and healthcare settings. In addition, MRSA strains 
increasingly have developed varying degrees of resistance to vancomycin, the accepted 
treatment standard13, and hospital-associated health care costs for patients with MRSA-
related infections are nearly double those of patients with methicillin-sensitive S. aureus14.
Multi-drug resistant PA and MRSA are treated with antibiotics that target specific bacterial 
reactions or enzymes to inhibit cell replication, cell wall biosynthesis, or they may kill 
bacteria directly. Antibiotic exposure enables bacteria to acquire resistance through 
mutations that allow for target drug degradation, reduced drug affinity to target sites, altered 
metabolic pathways, and/or reduced drug accumulation15–17. For example, ciprofloxacin 
inhibits bacterial replication by inhibiting DNA gyrase and topoisomerase IV, thereby 
blocking bacterial cell division18. CipR PA acquire mutations to DNA gyrase and or 
topoisomerase to escape its lethal antibiotic effects and by active removal of ciprofloxacin 
via broad substrate efflux pumps to expel the drug and prevent its accumulation within 
cells17. On the other hand, vancomycin inhibits bacterial cell wall biosynthesis by binding to 
the C-terminal D-Ala-D-Ala of pentapeptide peptidoglycan precursors to block 
transpeptidation19. Heteroresistance to vancomycin in MRSA reportedly results from 
repeated vancomycin exposure selecting for a thickened cell wall that blocks vancomycin 
from its target site20, and this resistant phenotype has accounted in part for persistence of 
bacteremia and increased mortality21, 22. One approach to facilitate the treatment of anti-
biotic-resistant infections may be to combine current therapies with broad-spectrum peptide 
microbicides that kill bacteria by general, independent mechanisms such as membrane 
disruption.
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Mammalian defensins are 2–5 kDa, broad spectrum, cationic antimicrobial peptides, with 
structures that are defined by specific tridisulfide arrays23. The α-, β-, and θ- defensins 
compose the mammalian defensin family, and each subfamily differs with respect to 
structural features that are imposed by specific disulfide connectivities, and they have 
distinct primary sites of expression24. For example, the α-defensin tridisulfide array is 
characterized by conserved CI–VI, CII–IV, CIII–V cysteine pairings, and β-defensins are 
characterized by a CI–V, CII–IV, CIII–VI disulfide connectivity25. α-Defensin genes are 
expressed by promyelocytes mainly accumulate in neutrophil azurophil granules, and those 
expressed by Paneth cells are secreted into the small intestinal lumen. Certain β-defensins, 
on the other hand, are expressed widely by epithelia at diverse mucosal barrier 
interfaces26, 27. θ-Defensins are the only macrocyclic peptides known in the animal kingdom 
and are expressed in the bone marrow of only Old World monkeys. The peptides derive 
from truncated α-defensin genes, assemble from two hemi-precursors, and contain a 
tridisulfide array that is arranged in the form of a parallel ladder28.
The mechanisms of defensin microbicidal activity have been investigated extensively29. 
Based on in vitro studies, micromolar levels of α-defensins may disrupt microbial 
membranes selectively by inducing either stable or transient defects of variable size in 
model membranes composed of microbial phospholipids30, 31. Induction of membrane 
defects leads to target cell permeabilization, K+ efflux, depolarization, dissipation of 
electrochemical gradients, leakage, and eventual cell death32–35. Analyses of defensin-
bilayer in5 teractions by small angle X-ray scatter, showed that mouse Paneth cell α-
defensin cryptdin-4 (Crp-4), rhesus myeloid α-defensin RMAD-4, and the rhesus θ-defensin 
RTD-1 induce negative Gaussian, or saddle splay, curvature to create pores in model 
membranes and facilitating membrane disruption36. On the other hand, at lower peptide 
concentrations defensins can also inhibit bacterial peptidoglycan synthesis by lipid II 
binding37, 38, and defensins may use a lipid II binding mechanism to exert antimicrobial 
effects.
Because α-, and θ-defensins kill bacteria by these general mechanisms, which differ from 
those of ciprofloxacin and vancomycin, we reasoned that vancomycin-heteroresistant 
MRSA and CipR PA may be susceptible to the microbicidal effects of exposure to these 
defensin peptides. To test this hypothesis, the survival of clinical isolates of 
vancomycinheteroresistant MRSA and CipR PA exposed to Crp4, RMAD-4, RTD-1, and 
human neutrophil α-defensins HNPs 1–3 were determined. Under the conditions of the in 
vitro bactericidal assays, nearly all MRSA and PA strains were sensitive to all peptides 
except for HNPs, irrespective of antibiotic resistance. In addition, PA sensitivity to α-
defensins was not related to site of isolation, degree of ciprofloxacin resistance, TTSS 
effector genotype, or cytotoxic potential. Because Crp-4, RMAD-4, and RTD-1 are non-
hemolytic, resistant to proteolytic degradation, and among the most potent known defensins, 
they may offer promise for development of novel antimicrobial therapeutics.
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MATERIALS AND METHODS
Peptide Preparation
Peptides (Figure 1) were purified to homogeneity by reverse phase high performance liquid 
chromatography (RP-HPLC), and their identities were confirmed by MALDI-TOF MS and 
by acid-urea polyacrylamide gel electrophoresis (AU-PAGE) as described39, 40. 
Recombinant Crp-4 and RMAD-4 peptides were expressed in Escherichia coli as N-terminal 
His6-tagged fusion proteins using the pET28a expression system (Novagen, Inc. Madison, 
WI)32, 41, 42. Crp-4 and RMAD-4 templates were cloned in pCR-2.1 TOPO, verified by 
DNA sequencing, subcloned into pET28a plasmid DNA (Novagen, Inc., Madison, WI), and 
transformed into E. coli BL21(DE3)-CodonPlus-RIL cells (Stratagene) for recombinant 
expression32, 41. His6-tagged Crp-4 fusion peptides were purified using nickel-nitrilotriacetic 
acid (Ni-NTA, Qiagen) resin affinity chromatography43. After CNBr cleavage of the His6 
tag, peptides were purified by sequential C18 reverse-phase high performance liquid 
chromatography (RP-HPLC), and molecular masses of purified peptides were determined 
using MALDI-TOF MS on a Bruker Microflex LRF (Bruker, Fremont, CA). Solution 
structures of recombinant peptides prepared by this approach have been determined by 
NMR44, 45.
Human neutrophil peptides (HNPs) were isolated from samples enriched in neutrophils 
granules prepared from peripheral blood leukocytes46, 47. Briefly, after removing platelets 
from human blood by centrifugation at 200 × g for 10 min and hypotonic lysis of red blood 
cells, the leukocyte-enriched cell fraction was resuspended in 0.34 M sucrose, pH 7.4, 
homogenized, and cellular debris deposited by centrifugation at 200 × g for 10 min, leaving 
a granule-rich supernatant. Granules deposited by 30 min centrifugation at 27,000 × g at 4°C 
were extracted for 18 h at 4°C with 10% acetic acid, and protein extracts were clarified by 
centrifugation at 27,000 × g for 30 min at 4°C. A mixture of natural HNPs 1–3 was purified 
by gel permeation chromatography using BioGel P10 (Bio-Rad Laboratories, Hercules, CA). 
HNP-2 was purified further from pooled HNPs 1–3 by C18 RP-HPLC.
RTD-1 was synthesized as previously reported48. Synthetic RTD-1 is structurally and 
biologically indistinguishable from peptide isolated from rhesus monkey neutrophils28.
Clinical Isolates
Bacterial isolates were grown from culture specimens obtained from hospitalized patients at 
Huntington Hospital, Pasadena, CA as part of a longitudinal epidemiologic surveillance 
study of resistant pathogens at the institution and were stored at −80°C until testing. All data 
were analyzed anonymously. Susceptibility of MRSA isolates to vancomycin was 
determined by Etest-based method according to manufacturer’s instructions (bio- Meriéux, 
Durham, NC). Specifically, vancomycin heteroresistant phenotype was determined using the 
Etest Glycopeptide Resistance Detection (GRD) method49. PA susceptibility to 
ciprofloxacin was performed by broth microdilution method as recommended by the 
Clinical Laboratory Standards Institute, with ciprofloxacin resistance defined by mini7 mum 
inhibitory concentration of 2 µg/ml or greater. As for PA strains, genes encoding the TTSS 
effector proteins ExoU and ExoS were assayed by polymerase chain reaction as before50. In 
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vitro experiments were performed to determine PA cytotoxicity by infecting A549 lung 
epithelial cells at a multiplicity of infection (MOI) of 10 and measuring LDH release at 3 h 
post-infection using the CytoTox96 assay kit (Promega, Madison, WI).
MRSA bloodstream isolates and PA strains that caused pneumonia, as well as bacteremia, 
wound and urinary tract infections were selected for this study to represent clinical isolates 
that exhibit varying degrees of resistance to vancomycin (MRSA) and ciprofloxacin (PA), 
respectively. The MRSA cohort included strains that caused persistent blood-stream 
infection and different molecular epidemiologic characteristics; PA strains included those 
with different virulence potential based on TTSS effector genotype and the rate and extent 
of cytotoxicity observed in A549 cells. Two additional reference MRSA strains with 
heteroresistance (Mu3) and intermediate resistance (Mu50) to vancomycin also were 
studied.
In vitro Bactericidal Assays
The α- and θ-defensins were tested for bactericidal activity against clinical isolates of 
MRSA and PA in in vitro cell suspension assays32, 41. Bacteria grown to midexponential 
phase in trypticase soy broth were deposited by centrifugation at 10,000 × g for 3 min, and 
washed 3 times with 10 mM piperazine-1,4-bis(2-ethanesulfonic acid) (PIPES), pH 7.4, 
supplemented with 1% (vol/vol) of trypticase soy broth (10 mM PIPES-TSB, pH 7.4). In 
triplicate, 1–5 × 106 bacterial colony forming units (CFU)/ml were exposed to peptides in 50 
µl 10 mM PIPES-TSB in 96-well polystyrene plates. Samples were incubated at 37°C with 
shaking for 1 h, diluted 1:100 in 10 mM PIPES (pH 7.4), and plated on TSB agar plates 
using an Autoplate 4000 (Spiral Biotech Inc., Bethesda, MD). Bacterial cell survival as a 
function of peptide exposure was determined by counting CFU after overnight growth at 
37°C. In these assays, after 1 h of peptide exposure replicate peptide-bacterial mixtures are 
plated with a plating stylus onto the agar plate surface. The assay enables bacteria that are 
not exposed or affected by peptide exposure to be enumerated, rather than produce lawns 
that cannot be counted. On the other hand, sample dilution limits the lower end of the assay, 
i.e., when >99.9% of exposed bacteria die. Because of the dilution factors involved, plates 
on which no CFU were detected after overnight incubation actually may have had between 1 
to 999 viable CFU in the peptide-bacterial mixture before dilution and plating. Accordingly, 
the limit of detection is ≤ 103 CFU/ml, when no CFU are detected, and the ordinates of 
bacterial survival curves are labeled in that manner.
RESULTS
Defensin sensitivity of vancomycin-heteroresistant MRSA strains
MRSA clinical isolates with varied resistance to vancomycin were exposed to Crp-4, 
RMAD-4, and RTD-1 to determine their sensitivities to the peptides. Against standard 
laboratory strains of S. aureus, Crp-4, RMAD-4, and RTD-1 are potent microbicides, 
reducing cell viability 1000-fold at low micromolar peptide concentrations51, 52. Here, 
Crp-4, RMAD-4, and RTD-1 similarly reduced viability of vancomycin-intermediate S. 
aureus (VISA) control strain Mu50 and heteroresistant VISA (hVISA) control strain Mu3 
with MBC values between 1.5 and 3 µM peptide (Table 1, Figs. 2A and B). Clinical isolates 
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characterized as hVISA by the Etest GRD method (Materials and Methods) were highly 
sensitive to all defensins tested (Figs. 2C and D), with RMAD-4 had the greatest bactericidal 
activity against every VISA/hVISA strain tested with 1.5 µM MBC values for all strains 
(Table 1, Figs. 2A–D).
The potent microbicidal effects of Crp-4, RMAD-4, and RTD-1 against VI-SA/hVISA 
control strains prompted us to test whether MRSA that had persisted in bacteremic patients 
after extensive vancomycin treatment would be sensitive to these defensins. Clinical blood 
isolates of MRSA that were not cleared by vancomycin treatment were assessed for survival 
after Crp-4, RMAD-4, and RTD-1 exposure in vitro, and all MRSA clinical isolates were 
sensitive to Crp-4, RMAD-4, and RTD-1 a peptide concentration dependent manner, 
regardless of response to vancomycin treatment (Table 1, Figs. 3A–F). For example, the 
MBC for RMAD-4 was 1.5 µM against vancomycin resistant and sensitive MRSA strains 
(Table 1, Fig. 3), and no association existed between antibiotic resistance and defensin 
susceptibility. Also, vancomycin-heteroresistant MRSA isolated from bacteremic patients 
that failed to resolve with antibiotic therapy were susceptible to the three defensins and as 
sensitive as culture adapted S. aureus strains (Table 1).
Sensitivity of ciprofloxacin-resistant PA to defensins
PA develops resistance to ciprofloxacin by mutations in DNA gyrase, topoisomerase IV or 
both and via efflux pumps that remove the drug and prevent its accumulation. Because the 
α-defensins in this study are membrane disruptive microbicides and peptide accumulation 
within target cells is not required for activity, we tested whether CipR PA are sensitive to 
Crp-4 and RMAD-4. Bactericidal assays against ciprofloxacin-sensitive (CipS) and CipR PA 
isolated from patient sputum showed that most PA sputum isolates were sensitive to both 
Crp-4 and RMAD-4 at low micromolar peptide levels, regardless of antibiotic resistance 
(Table 2, Fig. 4, See Supplementary Figure S1). In contrast to the variability of the relative 
activities of Crp-4 and RMAD-4 against MRSA (Table 1, Fig. 3), Crp-4 consistently was 
more active than RMAD-4 against most PA strains isolated from sputum (Table 2, Fig. 4). 
Also, sputum isolates displayed more variability than MRSA strains regarding susceptibility 
to Crp-4 and RMAD-4. Consistent with the defensin sensitivities of vancomycin-
heteroresistant MRSA strains, Crp-4 and RMAD-4 were bactericidal against PA sputum 
isolates irrespective of strain ciprofloxacin resistance, there being no association between 
PA isolate sensitivities to Crp-4 or RMAD-4 and antibiotic resistance.
The activities of defensins against PA sputum isolates were tested further by determining the 
in vitro bactericidal effects of RTD-1, a mixture of natural HNPs 1–3, and purified HNP-2 
against sputum PA isolates. RTD-1 at <1.5–6 µM reduced survival of the majority of sputum 
PA isolates to ≤ 103 CFU/ml, below the limit of detection for these assays (Fig. 5). In 
contrast, HNP 1–3 (Fig. 4A–C) and HNP-2 (Fig. 4D–F) did not affect survival of PA 
sputum isolates, even at peptide concentrations 10–fold greater than levels at which Crp-4 
and RTD-1 are highly microbicidal. Thus, HNPs, endogenous α-defensins that occur at 
elevated serum concentrations during septicemia and certain infections in humans53, lacked 
bactericidal activity against CipR and CipS PA strains under these in vitro conditions. 
Although HNPs lacked activity against PA strains, they have been shown to have alternative 
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innate host defense roles, including neutralization of anthrax lethal toxin and as 
chemoattractants54, 55. Because PA isolates were sensitive to Crp-4 and RMAD-4 
irrespective of antibiotic resistance, we focused on characterizing the activities of those 
molecules rather than optimizing the activities of HNPs. Perhaps, the non-human peptides, 
Crp-4, RMAD-4, and RTD-1, may offer promise as adjunct therapies for treatment of 
bacterial infections that fail to resolve with conventional treatment.
PA sensitivity to α-defensins is independent of the site of isolation
Major sites of PA infections include the urinary tract, lungs of cystic fibrosis patients, and 
burn wounds, and PA strains may differ phenotypically, depending on the site of infection56. 
Accordingly, bactericidal peptide assays were performed against PA clinical isolates from 
patient urine (Fig. 6A, B, C, See Supplementary Figure S2), burn wounds (Fig. 6D, E, F, See 
Supplementary Figure S3), and blood (Fig. 6G, H, I) to test their sensitivities to Crp-4 and 
RMAD-4. Crp-4 was highly bactericidal against almost every PA isolate, irrespective of the 
site of strain isolation. When exposed to ≥ 6 µM Crp4, no PA survivors were detected on 
plates, i.e., ≤ 103 CFU/ml survived peptide exposure (Figure 6). RMAD-4 had similar 
activities against PA wound isolates, but PA strains from blood and urine were more 
variable in RMAD-4 susceptibility (Table 3). Therefore, little relation exists between the site 
of PA strain isolation and resistance to these α-defensins.
ExoU or ExoS PA genotype and cytotoxicity do not induce α-defensin resistance
Most wild-type PA strains harbor the exoS gene encoding the TTSS effector protein, and 
CipR PA populations are enriched for the exoU gene that codes for a TTSS effector protein, 
which contributes to virulence in acute infection50, 57. Notably, ExoU expressing PA are 
more virulent than ExoS strains in a murine model of acute pneumonia, and they cause more 
severe disease in humans11, 58. To test whether these PA virulence geno-types have 
differential α-defensin sensitivities, we performed bactericidal assays and determined 
whether ExoU or ExoS genotype and α-defensin resistance are related a significantly by 
constructing contingency tables and performing a Fisher’s exact test. We also grouped the 
PA strains on the basis of the rate and extent of their cytotoxic effects on exposed A549 lung 
epithelial cells, and we compared strain α-defensin susceptibility to cytotoxic potential. For 
this purpose, PA sputum isolates were categorized as α-defensin resistant if less than 99% 
killing occurred when exposed to 6 µM peptide. A subset of ExoU PA strains were resistant 
to Crp-4 and RMAD-4 by this definition (Fig. 7), but no significant association existed 
between genotype and α-defensin resistance (p>>0.1). Reduced sensitivity to Crp-4 or 
RMAD-4, therefore, was not determined by TTSS effector genotype. Similarly, Crp4 and 
RMAD-4 bactericidal activities against sputum isolates were independent of PA cytotoxic 
potential, because highly cytotoxic strains (05038 and ML172) or non-cytotoxic strains 
(06161 and ML75) were equally peptide sensitive (Fig. 7). Collectively, these studies show 
that the bactericidal activities of Crp-4 and RMAD-4 against PA clinical isolates are 
independent of CipR status, site of isolation, TTSS effector genotype, and cytotoxic 
potential.
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DISCUSSION
Antimicrobial peptides have been proposed as templates for developing new therapeutics to 
combat multidrug resistant pathogens59, 60, yet the efficacy of α-defensins against antibiotic 
resistant clinical isolates has not been investigated extensively. Because general mechanisms 
of α-defensin microbicidal action differ from most antibiotics, they may be useful in 
combating infections by synergizing in combination with current antibiotic therapies. 
Because Crp-4, RMAD-4, and RTD-1 resist proteolysis and are non-cytotoxic, potent 
microbicides in vitro, they may provide new peptide-based platforms for antibiotic 
development39, 61. To test the hypothesis that Crp-4, RMAD-4, and RTD-1 may be 
efficacious against clinically important bacteria that also are antibiotic resistant, we assayed 
the bactericidal activities of these defensins against isolates of MRSA with varying 
resistance to vancomycin and CipR-PA. Under the in vitro assay conditions, Crp-4, 
RMAD-4, and RTD-1 were highly active against MRSA and exhibited differential activities 
against PA, irrespective of antibiotic resistance.
The continuing emergence of MRSA strains with vancomycin resistance, the treatment 
standard, underscores the need for new therapeutics. Against all strains of MRSA tested, 
Crp-4, RMAD-4, and RTD-1 were highly active with MBC values of 1.5–3 µM peptide, 
regardless of vancomycin resistance. In addition, RMAD-4 had a low MBC of 1.5 µM 
peptide, the lowest concentration assayed, against all but one MRSA strain. The α- 
defensins investigated have microbicidal mechanisms of action that that disrupt cellular 
integrity62. For example, certain defensins kill bacteria by sequestering lipid II and 
inhibiting bacterial cell wall biosynthesis37, 63, 64, HNPs 1–3 mediate non-oxidative 
microbial cell killing by sequential permeabilization of the outer and inner membranes and 
formation of stable pores65, and Crp-4, RMAD-4, and RTD-1 disrupt membranes by 
forming transient pores by induction of saddle-splay curvature66. At concentrations 
approximately 10-fold greater than the MBC values reported here, Crp4 induces rapid efflux 
of potassium ions from bacterial cells, a sensitive indicator of membrane disruption and cell 
death67–6934, 70. We do not discount inhibition of cell wall biosynthesis as contributing to 
the defensin mechanism of action in certain settings. On the other hand, over the one-hour 
course of peptide exposure in the experiments we have presented, membrane disruption is 
the most likely mechanism of action36, 71, a mechanism that differs from beta lactam 
inhibitors and vancomycin. Thus, in combination with antibiotics, these defensin peptides 
could synergize with current antibiotics to improve treatment of MRSA-related infections.
Gram-negative bacteria account for more than 30% of US hospital infections and are the 
predominant ICU infections72–74. For example, PA is a leading cause of pneumonia, urinary 
tract, and bloodstream infections72, and the incidence of multidrug resistant PA is rising75. 
Crp-4, RMAD-4, RTD-1, and HNP 1–3 were tested against PA strains characterized by their 
ciprofloxacin resistance, site of isolation, TTSS effector genotype and cytotoxic potential to 
determine whether these traits correlated with defensin resistance. Under the conditions of 
the in vitro assays, PA strains exhibited variable sensitivity to the defensin peptides tested 
(Tables 2, 3), but defensin sensitivity was not associated with either of the phenotypic 
characteristics. Cationic charge contributes to defensin bactericidal activity, but even though 
Crp-4 and RMAD-4 are equally electropositive, Crp-4 was more active against PA strains 
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but RMAD-4 was more potent against MRSA (Tables 1–3). Perhaps, the differential 
bactericidal effects are due to differences in the surface charge or hydrophobicity 
distribution of the two α-defensin peptides51. Although PA isolates from lung, blood, and 
urine differ phenotypically56, the strains tested were equally sensitive to Crp-4 and 
RMAD-4, irrespective of their site of isolation.
The α-defensin and θ-defensin peptides tested hold promise toward the eventual 
development of new therapeutic agents against the growing number of antibiotic resistant 
pathogens. Although Crp-4, RMAD-4, and RTD-1 are highly active against many of the PA 
strains tested in vitro, activity against PA strains may be diminished in the setting of chronic 
lung infections where biofilm formation is induced76, 77, in that biofilm production enhances 
resistance to bactericidal peptides. Whether biofilms diminish the activities of peptides 
tested here is unknown78. Also, the ionic strength of assay media inhibits bactericidal 
activities of Crp4 and RMAD-4, and binding of Crp-4, RMAD-4, and RTD-1 peptides to 
plasma proteins has not been studied and may limit efficacy in vivo. Against bacteria that are 
sensitive to these peptides, e.g., MBC ≤1.5 µM, bactericidal effects of Crp-4 and RMAD-4 
are partially inhibited by 50 mM NaCl and completely inhibited at 100 mM NaCl. Thus, the 
inherent salt sensitivity of these native molecules may limit therapeutic application of native, 
full-length α-defensins, but reiterative selection of salt-insensitive variants of these peptides 
could lead to drug development based on these peptide scaffolds. In contrast to the α-
defensins, however, cyclized RTD-1 is as active in 150 mM NaCl as in low salt 
media28, 48, 52, an indication that the θ-defensins may provide a more robust platform for 
therapeutic development. Also, the disulfide array protects the Crp-4 and RMAD-4 from 
proteolytic degradation, and α-defensins can be recovered from the protease- rich 
environment of the mouse small and large bowel61, 79. Biophysical studies of Crp-4, 
RMAD-4, and RTD-1 have established amino acid criteria necessary for their selective 
membrane disruptive activities29, and Crp-4 and RMAD-4 are non-cytotoxic and 
nonhemolytic at peptide concentrations as high as 100 µg/ml (data not shown)52.
In addition to their broad spectrum in vitro microbicidal activities, rhesus θ- defensins 1–5 
(RTDs 1–5), RTD-1 in particular, reduced the levels of TNF-α, IL-1α, IL- 1β, IL-6, and 
IL-8 released by mixed blood leukocytes and THP-1 monocytes stimulated by bacteria or 
LPS, respectively80. Also, systemic administration of RTD-1 to BALB/c mice was non-toxic 
and stable in serum and plasma, and intravenous delivery of 5 mg/kg RTD-1 significantly 
improved survival of BALB/c mice with E. coli peritonitis and cecal ligation-and-puncture-
induced polymicrobial sepsis80. In contrast to HNPs, which are proinflammatory81–85, Crp4 
and RMAD4 also inhibit cytokine and TNF-α release in the same in vitro assays, although 
both are less inhibitory than RTD-1 (Kamdar et al., submitted for publication). Thus, new 
antimicrobials that are developed to optimize both defensin-based bactericidal and 
immunomodulatory properties may prove to be efficacious in combination with current 
antibiotic therapies against antibiotic resistant bacteria while promoting survival from 
systemic infections.
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Figure 1. Primary structures of α- and θ-defensins
The primary structures of peptides investigated are aligned; net overall charge is shown at 
right. α-Defensins are aligned by their conserved Cys residues (in bold), and their CI-CVI, 
CII-CIV, and CIII-CV disulfide connectivities are depicted by brackets. The α-defensins from 
mouse Paneth cells and rhesus neutrophils are highly cationic as compared to the human 
myeloid peptides, HNPs 1–3. The octadecapeptide RTD-1, a θ-defensin, is a macrocyclic 
peptide identified in rhesus macaque neutrophils and found only in Old World monkeys.
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Figure 2. Sensitivity of control MRSA strains to RMAD-4, Crp-4, and RTD-1 is independent of 
antibiotic resistance
Bactericidal peptide assays were performed in triplicate as described (see Materials and 
Methods). Briefly, MRSA strains were exposed to peptides for 1 h, and surviving bacteria 
were counted as CFU/ml at each peptide concentration (see Materials and Methods). Values 
≤ 1 × 103 CFU/ml signify that no colonies were detected on plates after overnight growth. 
Strain Mu50 (A) is a vancomycin-intermediate S. aureus (VISA) control, and Mu3 (B), 
DH290 (C), and DH280 (D) are classified as heteroresistant VISA (hVISA) strains. Each 
condition was performed in triplicate, with error bars denoting standard deviations from the 
mean. Symbols: Crp-4 (-●-), RMAD-4 (-○-), and RTD-1 (-▼-).
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Figure 3. MRSA sensitivity to RMAD-4, Crp-4 and RTD-1 is not associated with antibiotic 
resistance
Bactericidal peptide assays were performed in triplicate as described (Fig 2, Materials and 
Methods). Strains EB151 (A), EB123 (B) and EB135 (C) are clinical isolates from patients 
whose infections were cleared by vancomycin administration, in contrast to strains JJ593 
(D), EB77 (E) and EB378 (F) which were isolated from persistent infections after failure of 
treatment with vancomycin. All MRSA strains were sensitive to the defensins tested at low 
micromolar concentrations (Table 1). Each condition was performed in triplicate with error 
bars denoting standard deviation from the mean. Symbols: Crp-4 (-●-), RMAD-4 (-○-), and 
RTD-1 (-▼-)
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Figure 4. Activities of Crp-4 and RMAD-4 against CipR and CipS strains of PA
Bactericidal peptide assays were performed in triplicate against clinical isolates from patient 
sputum. Isolates 06397 (A), ML43 (B), and 06324 (C) are CipR-PA, and isolates 05080 (D), 
06161 (E), and ML172 (F) are CipS-PA. No correlation exists between antibiotic resistance 
and α-defensin activity (Table 2). Bars denote standard deviations from the mean. Symbols: 
Crp-4 (-●-) and RMAD-4 (-○-).
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Figure 5. Attenuated activities of HNPs against PA clinical isolates
Survival of CipS P. aeruginosa strains 06397 (A), ML43 (B), and ML121 (C) and CipR–PA 
strains 06161 (D), 05038 (E), and ML172 (F) isolated from patient sputum was measured 
after exposure to Crp-4, RTD-1, and HNPs. In contrast to Crp-4 and RTD-1, 60 µM HNPs 
had little bactericidal effects against P. aeruginosa, irrespective of CipR. RTD-1 and HNPs 
assays were performed in triplicate, Crp-4 activity, assayed once at each peptide 
concentration, was consistent with Fig. 3 Error bars denote standard deviations from the 
mean.
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Figure 6. α-Defensin sensitivity is independent of the site of PA isolation
P. aeruginosa strains WB 25 (A), WB 36 (B), WB 34 (C) isolated from the urine of patients, 
strains WB 12 (D), WB 35 (E), and WB 44 (F) isolated from patient wounds, and WB 42 
(G), WB 16 (H), and WB 15 (I) isolated from patient blood were exposed to 1.5–6 µM 
peptides (Table 3). Assays were performed in triplicate; error bars denote standard deviation 
from the mean. Symbols: Crp-4 (-●-) and RMAD-4 (-○-).
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Figure 7. Crp-4 or RMAD-4 bactericidal activity against PA are independent of ExoU or ExoS 
genotype and cytotoxic potential
PA sputum isolates, characterized as ExoU (Black) or ExoS (white) are arranged in order of 
increasing bacterial survival following exposure to 6 µM of Crp-4 or RMAD-4. Cytotoxic 
potentials of each strain are also indicated by asterisks. PA strains were considered resistant 
if > 1% of bacteria survived α-defensin peptide exposure. TTSS effector genotypes and 
defensin resistance are not associated (p>0.1), and bactericidal activities were independent 
of PA cytotoxic potential.
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Table 1
Defensin MBC Values against VISA and hVISA MRSA Strains
MBC Value (µM)
MRSA Strain Crp-4 RMAD-4 RTD-1
Mu50 (VISA) 3 1.5 3
Mu3 (hVISA) 1.5 3 1.5
DH 290 (hVISA) 3 1.5 3
DH280 (hVISA) 3 1.5 1.5
EB151§ 1.5 1.5 1.5
EB123§ 3 1.5 3
EB135§ 3 1.5 3
JJ593‡ 1.5 1.5 1.5
EB77‡ 3 1.5 3
EB378‡ 3 1.5 3
§
Infection cleared by vancomycin administration.
‡
Persistent infection with vancomycin administration.
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Table 2
α-Defensin MBC Values against CipR and CipS strains of Pseudomonas aeruginosa
P. aeruginosa strain MBC Value (µM)
Crp-4 RMAD-4
06397 (CipS)† 1.5 3
ML43 (CipS) 1.5 1.5
06324 (CipS) 1.5 1.5
05080 (CipR)§ 1.5 1.5
06161 (CipR) 1.5 1.5
ML172 (CipR) 1.5 1.5
†
CipS denotes ciprofloxacin-resistant strains;
§
CipR denotes ciprofloxacin-resistant strains.
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Table 3
α-Defensin MBC Values against P. aeruginosa Blood, Urine, and Wound Isolates
P. aeruginosa strain MBC Value (µM)
Crp-4 RMAD-4
WB 25 (U)† 3 6
WB 36 (U) 1.5 6
WB 34 (U) 1.5 >6
WB 12 (W)‡ 1.5 3
WB 35 (W) 1.5 3
WB 44 (W) 1.5 3
WB 42 (B) 1.5 1.5
WB 16 (B) 1.5 1.5
WB 15 (B) 1.5 1.5
Symbols denote anatomic source of the clinical isolates:
†
Urine,
‡
Wounds,
§
Blood.
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